Interferon \( \gamma \) Inhibits Apoptotic Cell Death in B Cell Chronic Lymphocytic Leukemia

By Michael Buschle,* Dario Campana,* Simon R. Carding,† Carlos Richard,§ A. Victor Hoffbrand,‖ and Malcolm K. Brenner*

From the *Division of Bone Marrow Transplantation, Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee 38101, and the Departments of Pediatrics and Medicine, Memphis College of Medicine, University of Tennessee, Memphis, Tennessee 38163; the †Department of Microbiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104; the ‡Department of Haematology, Hospital Marques de Valdecilla, Santander, Spain; and the ‖Department of Haematology, Royal Free Hospital School of Medicine, London NW3-2QP, United Kingdom

Summary

The malignant, CD5\(^+\) B lymphocytes of B cell chronic lymphocytic leukemia (B-CLL) die by apoptosis in vitro. This is in contrast to the prolonged life span of the leukemic cells in vivo and likely reflects the lack of essential growth factors in the tissue culture medium. We found that interferon \( \gamma \) (IFN-\( \gamma \)) inhibits programmed cell death and promotes survival of B-CLL cells in culture. This effect may also be important in vivo: increased serum levels of IFN-\( \gamma \), ranging from 60 to >2,200 pg/ml, were found in 7 of 10 B-CLL samples tested, whereas the sera of 10 healthy individuals did not contain detectable levels of this cytokine (<20 pg/ml). High levels of IFN-\( \gamma \) message were detected in RNA from T cell–depleted B-CLL peripheral blood samples by Northern blot analysis. Synthesis of IFN-\( \gamma \) by B-CLL lymphocytes was confirmed by in situ hybridization and flow cytometry. The majority of B-CLL cells (74–82%) expressed detectable levels of IFN-\( \gamma \) mRNA, and CD19\(^+\) B-CLL cells were labeled with anti-IFN-\( \gamma \) monoclonal antibodies. These results show that IFN-\( \gamma \) inhibits programmed cell death in B-CLL cells and suggest that the malignant cells are able to synthesize this cytokine. By delaying apoptosis, IFN-\( \gamma \) may extend the life span of the malignant cells and thereby contribute to their clonal accumulation.

B cell chronic lymphocytic leukemia (B-CLL) is characterized by the slow and progressive accumulation of monoclonal, apparently mature, CD5\(^+\) B lymphocytes (1). The majority of circulating cells appear to be nondividing (2), and it has been suggested that a prolonged life span is mainly responsible for the accumulation of the leukemic cells (3).

The absence of growth factors induces programmed cell death (apoptosis) in many cultured lymphohemopoietic cells. For example, growth factor–dependent cell lines and IL-2-dependent T lymphocytes initiate apoptosis after the appropriate factors are withdrawn (4). When B-CLL samples are placed in culture, apoptosis occurs despite the presence of FCS in the tissue culture medium (5).

Thus, apoptosis in cultured B-CLL cells may be triggered by the absence of a survival-promoting factor (or factors), present in vivo. The identification of such a molecule would not only increase our understanding of pathogenesis in B-CLL, but might ultimately allow the development of targeted treatment.

The CD5\(^+\) B cells that accumulate in B-CLL are rare in normal peripheral blood (6). Whether normal or malignant human CD5\(^+\) B cells respond to different survival or proliferation signals than CD5\(^-\) B cells is not yet clear. However, it has been shown that administration of IFN-\( \gamma \) shortens the life span of the F<sub>i</sub> hybrids of New Zealand Black and New Zealand White mice (7) in which elevated levels of Ly-1\(^+\) B cells, the murine equivalent of human CD5\(^+\) B lymphocytes, parallel the progression of autoimmune disease (6). Furthermore, injection of anti-IFN-\( \gamma \) antibodies significantly prolonged survival of the animals compared with untreated controls (7).

These observations prompted us to examine the effects of IFN-\( \gamma \) on CD5\(^+\) B cells from patients with B-CLL and to test the hypothesis that IFN-\( \gamma \) acts as a survival signal for these cells. This study provides evidence that IFN-\( \gamma \) inhibits programmed cell death in cultured B-CLL cells. We also present data suggesting that IFN-\( \gamma \) may promote survival of B-CLL cells in vivo and that this cytokine is produced by the malignant cells themselves.

Materials and Methods

Samples: Sterile heparinized peripheral blood samples were obtained from nine B-CLL patients and five normal individuals. Serum
samples were obtained from 10 additional patients and 10 healthy volunteers. Diagnosis of B-CLL was unequivocal according to clinical, morphologic, and immunologic criteria. None of the patients had received chemotherapy for at least 3 mo before the samples were drawn; serum samples were obtained from previously untreated patients. Fresh and cryopreserved B-CLL cells were studied. Mono nuclear cells were isolated by two consecutive centrifugations on Ficoll-Hypaque density gradient (Lymphoprep; Nyegard, Oslo, Norway). B-CLL cells were further purified by depletion of monocytes by adherence to plastic tissue culture dishes (Nunc, Roskilde, Denmark). For RNA analysis T cells were depleted (see below). B-CLL cell preparations contained >90% CD19+ cells, >90% CD5+ cells, <5% CD2+ cells, and <1% CD14+ cells as assessed by staining with mAbs (AMAC, Inc., Westbrook, ME). Trypan blue excluding cells exceeded 95% in all cases studied.

Cell Culture. Separated cells were cultured at a concentration of 1-2 x 10^6 cells/ml RPMI 1640 supplemented with 10% heat-inactivated FCS (batch 9MO57; Whittaker M.A. Bioproducts, Walkersville, MD) and antibiotics. The following recombinant cytokines were used at the final concentrations indicated: 100 U/ml IL-1 (Hoffmann-La Roche, Inc., Nutley, NJ), 1,000 U/ml IL-2, (Cetus Corp., Emeryville, CA), 50 ng/ml IL-6 (Sandoz Pharmaceuticals, East Hanover, NJ), 25 ng/ml IL-7 (R. & D systems, Minneapolis, MN), and 100 U/ml IFN-γ (sp act, 3 x 10^7 U/mg; Genentech, South San Francisco, CA). 12-O-tetradecanoylphorbol 13-acetate (TPA; Sigma Chemical Co., St. Louis, MO), which has been shown to prevent apoptosis of B-CLL cells (8), was used at a final concentration of 2 x 10^-7 M. After initial titration, IFN-γ was added daily at a final concentration of 100 U/ml.

Measurement of Soluble IFN-γ. Serum samples were analyzed for the presence of IFN-γ by an ELISA (Bethesda Research Laboratories, Gaithersburg, MD), with an IFN-γ detection limit of 20 pg/ml.

Analysis of Apoptosis. Apoptosis was studied by light microscopy, by DNA gel electrophoresis, and flow cytometry. Cytocentrifuge preparations were stained with Wright-Giemsa for light microscopy analysis of apoptosis. 2 x 10^6 cells were assayed for Trypan blue excluding cells of CD19+ lymphocytes of four patients were labeled after apoptosis (Fig. 1). At the same time degradation of DNA into fragments of 180 bp and multiples was seen (Fig. 2). The forward and sideward light scattering changes of apoptotic cells (9; data not shown) also became apparent when cultured B-CLL cells were analyzed by flow cytometry. By day 5, only 56 ± 6.1% (mean ± SD) of the original cell number was recovered.

Addition of IFN-γ to the tissue culture medium inhibited apoptosis (Figs. 1 and 2). In the presence of IFN-γ (100 U/ml), 94 ± 3.6% (mean ± SD) of the CD19+ lymphocytes originally plated were recovered on day 5. IFN-γ was effective at a concentration of 25 U/ml with maximum inhibition achieved in the range of 100-1,000 U/ml (equivalent to ~3-30 ng/ml recombinant protein) and the effects of IFN-γ persisted for 7-9 d (data not shown).

Although IFN-γ prevented apoptosis, there was no evidence of cell proliferation as determined by staining with Ki-67, an antibody that recognizes a cell cycle-related antigen (13): <0.1% lymphocytes of four patients were labeled after 3 and 7 d of culture in the presence of 100 U/ml IFN-γ, confirming previous reports (14). In contrast to IFN-γ, IL-1, IL-2, IL-6, and IL-7 failed to prevent DNA degradation and to support survival (Fig. 2).

B-CLL Cells Synthesize IFN-γ. Next, we measured IFN-γ levels in sera from 10 B-CLL patients and in 10 healthy individuals. As illustrated in Fig. 3, IFN-γ was detected in sera from 7 of 10 B-CLL patients and 1 healthy individual. The amount of IFN-γ detected ranged from
IFN-γ levels in the sera tested did not correlate with the white blood cell count. Five samples with detectable IFN-γ were from patients at stage 0 of the disease according to Rai et al. (15), whereas the other two positive samples were from patients at stages I and II, respectively. The remaining three patients with no detectable IFN-γ levels in the serum were at stage 0. None of the patients had clinical signs of infection. No IFN-γ (<20 pg/ml) was detectable in sera from 10 healthy volunteers.

IFN-γ synthesis by B-CLL cells in vitro was studied at the RNA and protein level. For Northern analysis, three samples with <2% CD21 lymphocytes were selected. B-CLL cells produced IFN-γ mRNA rapidly and at high levels upon activation with TPA and calcium ionophore (Fig. 4). By in situ hybridization using antisense RNA probes, the majority of B-CLL cells in two cases tested (74 and 82%) were found to synthesize IFN-γ transcripts (Fig. 5).

Using double-color immunofluorescence and flow cytometry, we found that in normal peripheral blood samples acti-
B-CLL cells synthesize IFN-γ mRNA. RNA from B-CLL cells was analyzed for expression of IFN-γ message after stimulation with TPA and calcium ionophore for 6 h. CD2+ cells represented <2% of each sample tested. Filters were rehybridized with β-actin, indicating the relative amount of RNA loaded.

Figure 4. B-CLL cells synthesize IFN-γ mRNA. RNA from B-CLL cells was analyzed for expression of IFN-γ message after stimulation with TPA and calcium ionophore for 6 h. CD2+ cells represented <2% of each sample tested. Filters were rehybridized with β-actin, indicating the relative amount of RNA loaded.

Figure 5. In situ hybridization analysis of IFN-γ synthesis: the majority of B-CLL (74 and 82%) cells synthesize IFN-γ transcripts. Samples contained >99.5% CD19+ B lymphocytes. (A) B-CLL cells probed with IFN-γ sense transcripts (negative control). (B) B-CLL cells hybridized with a complementary IFN-γ RNA probe.

Figure 6. IFN-γ protein is synthesized by stimulated B-CLL cells. B-CLL lymphocytes and PBMC were stimulated with TPA and calcium ionophore for 24 h and stained simultaneously with CD19 and anti-IFN-γ mAbs as described in Materials and Methods. Preparations were analyzed by flow cytometry. (A) PBL: 8% CD19+ cells are labeled with anti-IFN-γ mAb. (B) B-CLL cells: 2.5% of the lymphocytes are CD19+/IFN-γ+; 0.5% CD19− cells were also labeled with anti-IFN-γ mAb. A representative experiment is shown.

Discussion

Alterations in the mechanisms leading to cell death may play an important role in the pathogenesis of cancer. Deviation from a programmed death mechanism could result in clonal accumulation of cells normally present at very low levels or representing a transitory cell type. Programmed cell death appears to be regulated by cytokines acting as survival signals (17). Thus, autocrine secretion or aberrant levels of certain cytokines could be responsible for delayed apoptosis and extended survival of malignant cells (18).

Our studies showed that IFN-γ can promote survival in malignant cells from patients with B-CLL. The potential in vivo relevance of this phenomenon is suggested by the detection of IFN-γ in the serum of 7 of 10 B-CLL cases tested. At the concentrations observed in vivo, this cytokine could indeed be responsible for prolonging the life span of the malignant cells.

IFN-γ may act directly on B-CLL cells or through the induction of, or in conjunction with, other factors. For example, it has been recently reported that IFN-γ increases expression of the CD23 antigen on the surface of B-CLL cells, and elevated levels of the soluble form of CD23, which prevents apoptosis of germinal center B cells (19), are also found.
in sera of B-CLL patients (20). IFN-γ is unlikely to induce proliferation of B-CLL cells, as cell numbers in IFN-γ-treated samples remained constant and we and others (14) did not find evidence for cell division of the leukemic cells after IFN-γ treatment. In vivo proliferation of B-CLL cells may be induced by other lymphokines such as TNF (21).

IFN-γ appears to be synthesized by the malignant, CD5 + B cells of patients with CLL. We were able to detect IFN-γ mRNA by Northern blot analysis and in situ hybridization in the majority of these malignant B lymphocytes. Furthermore, analysis of IFN-γ protein synthesis using double-color immunofluorescence and flow cytometry showed that CD19 + B-CLL lymphocytes contained high levels of this cytokine, suggesting an autocrine production of IFN-γ by the malignant B-CLL cells.

In conclusion, our results indicate that IFN-γ is a survival promoting factor for B-CLL cells and suggest that the malignant cells may contribute to the synthesis of the survival-promoting cytokine. Our observations may provide a rationale for novel therapeutic strategies based on inhibition of IFN-γ effects on B-CLL cells.

We thank Elaine Coustan-Smith for technical advice; Drs. John Cleveland, Harold Young, and Concha Bello-Fernandez for providing the IFN-γ cDNA probe and technical advice; Joyce Reittie for assistance with the collection of B-CLL samples; and Christy Wright for editorial assistance.

This work was supported by a grant from the National Cancer Institute (CA-21765; Core) and by the American Lebanese Syrian Associated Charities.

Address correspondence to Michael Buschle, Division of Bone Marrow Transplantation, Department of Hematology/Oncology, St. Jude Children's Research Hospital, P.O. Box 318, 332 North Lauderdale, Memphis, TN 38101-0318.

Received for publication 17 June 1992 and in revised form 7 October 1992.

References

1. Dighiero, G., P. Travade, S. Chevret, P. Fenaux, C. Chastang, J.L. Binet, and The French Cooperative Group on CLL. 1991. B-cell chronic lymphocytic leukemia: present status and future directions. Blood. 78:1901.

2. Orfao, A., J. Ciudad, M. Gonzalez, J.F. San Miguel, A.R. Garcia, M.C. Lopez-Berges, F. Ramos, M.C. Del Cañizo, A. Rios, M. Sanz, and A. Lopez Borrascas. 1992. Prognostic value of S-phase white blood cell count in B-cell chronic lymphocytic leukemia. Leukemia (Baltimore). 6:47.

3. Dameshek, W. 1967. Chronic lymphocytic leukemia: an accumulating disease of immunologically incompetent lymphocytes. Blood. 29:566.

4. Cohen, J.J. 1991. Programmed cell death in the immune system. Adv. Immunol. 50:55.

5. Collins, J.R., L.A. Verschuer, B.V. Harmon, R.L. Prentice, J.H. Pope, and J.F. Kerr. 1989. Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukemia cells following their culture in vitro. Br. J. Haematol. 71:343.

6. Hayakawa, K., and R.R. Hardy. 1988. Normal, autoimmune, and malignant CD5 + B cells: the Ly-1 B lineage. Annu. Rev. Immunol. 6:197.

7. Jacob, C.O., P.H. van der Meide, and H.O. McDevitt. 1987. In vivo treatment of (NZB × NZW)F1 Lupus-like nephritis with monoclonal antibody to γ interferon. J. Exp. Med. 166:798.

8. McConkey, D.J., M. Aguilar-Santelises, P. Hartzell, T. Eriksson, H. Mellstedt, S. Orrenius, and M. Jondal. 1991. Induction of DNA fragmentation in chronic B-lymphocytic leukemia cells. J. Immunol. 146:1072.

9. Manabe, A., E. Coustan-Smith, F.G. Behm, S.C. Raimondi, and D. Campana. 1992. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood. 79:2270.

10. Cleveland, J.L., M. Huleihel, P. Bressler, U. Siebenlist, L. Akhyama, R. Eisenman, and U.R. Rapp. 1988. Negative regulation of c-myc transcription involves myc family proteins. Oncogene Res. 3:357.

11. Carding, S.R., J. West, A. Woods, and K. Bottomly. 1989. Differential activation of cytokine genes in normal CD4-bearing T cells is stimulus dependent. Eur. J. Immunol. 19:231.

12. Schmid, I., C.H. Uittenbogaart, and J.V. Giorgi. 1991. A gentle fixation and permeabilization method for combined cell surface and intracellular staining with improved precision in DNA quantification. Cytometry. 12:279.

13. Gerdes, J., H. Lemmke, H. Batsch, H.-H. Wacker, U. Schwab, and H. Stein. 1984. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 133:1710.

14. Karray, S., T. Defrance, H. Merle-Béral, J. Banchereau, P. Debré, and P. Galanaud. 1988. Interleukin 4 counteracts the interleukin 2-induced proliferation of monoclonal B cells. J. Immunol. 168:85.

15. Rai, K.R., A. Szewetzky, E.P. Cronkite, A.D. Chanana, and R.N. Levy. 1975. Clinical staging of chronic lymphocytic leukemia. Blood. 46:219.

16. Young, H.A., and K.J. Hardy. 1990. Interferon-γ: Producer cells, activation stimuli, and molecular genetic regulation. Pharmacol. Ther. 45:137.

17. Raff, M.C. 1992. Social controls on cell survival and cell death. Nature (Lond.). 356:397.

18. Williams, G.T. 1991. Programmed cell death: Apoptosis and oncogenesis. Cell. 65:1097.

19. Liu, Y.-J., J.A. Cairns, M.J. Holder, S.D. Abbot, K.U. Jansen,
J.-Y. Bonnefoy, J. Gordon, and I.C.M. MacLennan. 1991. Recombinant 25-kDa CD23 and interleukin 1α promote the survival of germinal centre B cells: evidence for bifurcation in the development of centrocytes rescued from apoptosis. *Eur. J. Immunol.* 21:1107.

20. Fournier, S., G. Delespesse, M. Rubio, G. Biron, and M. Sarfati.

1992. CD23 antigen regulation and signaling in chronic lymphocytic leukemia. *J. Clin. Invest.* 89:1312.

21. Cordingley, E.T., A. Bianchi, A.V. Hoffbrand, J.E. Reittie, H.E. Heslop, A. Vyakarnam, M. Turner, A. Maeger, and M.K. Brenner. 1988. Tumor necrosis factor as an autocrine growth factor for chronic B-cell malignancies. *Lancet.* i:969.